Anti-TNF therapy and Crohn's disease;Anti-TNF et maladie de Crohn

Gastroenterologie Clinique et Biologique

Volumn 32, Issue 5 SUPPL. PART 1, 2008, Pages 478-481

  Peyrin Biroulet, L ^a  

^a CHU NANCY BRABOIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; INFLIXIMAB;

ARTICLE; COLONOSCOPY; CROHN DISEASE; DRUG EFFICACY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL RESEARCH; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; HUMANS; MALE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 50649112592     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2008.03.004     Document Type: Article

References (25)

1. Travis S.P., Stange E.F., Lemann M., Oresland T., Chowers Y., Forbes A., et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 55 Suppl. 1 (2006) i16-i35
2. Leung V.S., Nguyen M.T., and Bush T.M. Disseminated primary varicella after initiation of infliximab for Crohn's disease. Am J Gastroenterol 99 (2004) 2503-2504
3. Farrell R.J., Alsahli M., Jeen Y.T., Falchuk K.R., Peppercorn M.A., and Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 124 (2003) 917-924
4. Sany J., Kaiser M.J., Jorgensen C., and Trape G. Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis. Ann Rheum Dis 64 (2005) 1647-1649
5. Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Colombel J.F., Panaccione R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146 (2007) 829-838
6. Peyrin-Biroulet L., Laclotte C., and Bigard M.A. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther 25 (2007) 675-680
7. Peyrin-Biroulet L., Laclotte C., Roblin X., and Bigard M.A. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol 13 (2007) 2328-2332
8. Baert F., Noman M., Vermeire S., Van Assche G., D'Haens G., Carbonez A., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348 (2003) 601-608
9. Vermeire S., Noman M., Van Assche G., Baert F., D'Haens G., and Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 56 (2007) 1226-1231
10. Van Assche G., Paintaud G., Magdelaine C., D'haens G., Baert F., Vermeire S., et al. Concomitant immunosuppression does not impact on the outcome of maintenance infliximab therapy in Crohn's disease: final results of the imid trial. Gastroenterology 132 Suppl. 2 (2007) A103
11. Hanauer S.B., Wagner C.L., Bala M., Mayer L., Travers S., Diamond R.H., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2 (2004) 542-553
12. Rutgeerts P., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126 (2004) 402-413
13. Rutgeerts P., Diamond R.H., Bala M., Olson A., Lichtenstein G.R., Bao W., et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 63 (2006) 433-442
14. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
15. Sands B.E., Anderson F.H., Bernstein C.N., Chey W.Y., Feagan B.G., Fedorak R.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350 (2004) 876-885
16. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005) 2462-2476
17. Lichtenstein G.R., Diamond R.H., Wagner C., Olson A., Hegedus R., Bala M., et al. Infliximab administered as 3-dose induction followed by scheduled maintenance therapy in IBD: comparable clinical outcomes with or without concomitant immunomodulators. Gastroenterology 132 Suppl. 2 (2007) A146
18. Colombel J.F., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Panaccione R., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132 (2007) 52-65
19. Sandborn W.J., Feagan B.G., Stoinov S., Honiball P.J., Rutgeerts P., Mason D., et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357 (2007) 228-238
20. Mackey A.C., Green L., Liang L.C., Dinndorf P., and Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 44 (2007) 265-267
21. Toruner M., Loftus Jr. E.V., Harmsen W.S., Zinsmeister A.R., Orenstein R., Sandborn W.J., et al. Risk Factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134 (2008) 929-936
22. Clark M., Colombel J.F., Feagan B.C., Fedorak R.N., Hanauer S.B., Kamm M.A., et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 133 (2007) 312-339
23. Schreiber S., Khaliq-Kareemi M., Lawrance I.C., Thomsen O.O., Hanauer S.B., McColm J., et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 357 (2007) 239-250
24. Peyrin-Biroulet L., Deltenre P., Stalgis C., Sandborn W.J., and Colombel J.F. Achieving long-term maintenance of remission in Crohn's disease: are all anti-TNF created equal?. Gut 55 (2006) A131
25. Sandborn W.J., Hanauer S.B., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D.G., et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 56 (2007) 1232-1239